Almalki Mohammed E, Alshumrani Fahad A, Almalki Hussam A, Saati Asim A, Alzahrani Saeed E, Khouj Saleh M
Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, SAU.
Department of Interventional Cardiology and Structural Heart Disease, King Abdullah Medical City, Makkah, SAU.
Cureus. 2023 Jun 30;15(6):e41168. doi: 10.7759/cureus.41168. eCollection 2023 Jun.
We present the case of a 41-year-old man who developed myopericarditis after receiving the Pfizer COVID-19 vaccine. The patient experienced a sudden onset of chest and abdominal pain 16 days after vaccination. Electrocardiogram findings revealed deep T-wave inversion and minimal ST-segment elevation. Further investigation through coronary artery angiography and computed tomography identified an anomalous left main coronary artery. Magnetic resonance imaging confirmed the diagnosis of myopericarditis. This case highlights the importance of considering myopericarditis as a potential cause of chest pain and elevated cardiac biomarkers following COVID-19 vaccination, particularly in young individuals. Clinicians should be aware of this adverse event and include it in the differential diagnosis for patients presenting with similar symptoms after vaccination.
我们报告一例41岁男性在接种辉瑞新冠疫苗后发生心肌心包炎的病例。该患者在接种疫苗16天后突然出现胸痛和腹痛。心电图检查发现T波深倒置和ST段轻度抬高。通过冠状动脉造影和计算机断层扫描进一步检查发现左主干冠状动脉异常。磁共振成像确诊为心肌心包炎。该病例凸显了在新冠疫苗接种后,尤其是在年轻人中,将心肌心包炎视为胸痛和心脏生物标志物升高的潜在原因的重要性。临床医生应意识到这一不良事件,并将其纳入接种后出现类似症状患者的鉴别诊断中。